At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Presatovir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
In Brief
A Phase 2 clinical trial evaluating Presatovir and Placebo for Respiratory Syncytial Virus (RSV). Completed, enrolled 61 participants across 28 sites in 8 countries.
Detailed Summary
The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus (RSV)
CountriesAustralia, Belgium, Canada, France, Germany, Netherlands, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartDec 2015
Primary CompletionFeb 2017
Study CompletionSep 2017
TodayJul 2026
First PostedAug 27, 2015
Enrollment StartDec 31, 2015
Primary CompletionFeb 20, 2017
Study CompletionSep 27, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.8 years ago
Interventions
Presatovirdrug
Tablets administered orally or via nasogastric (NG) tube once daily
Placebodrug
Tablets administered orally or via NG tube once daily